An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines ...
More research is needed to confirm gray matter, the darker tissue found in the brain and spinal cord, “as a potential disease ...
The Amsterdam-based biotech firm said that its melt curve analysis-based test is used as a first-tier genetic screening tool to aid the diagnosis of SMA.
Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.
Biogen Inc. (BIIB) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New ...